Compare POLA & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POLA | PRPO |
|---|---|---|
| Founded | 1979 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Laboratory Analytical Instruments |
| Sector | Miscellaneous | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 32.4M |
| IPO Year | 2016 | N/A |
| Metric | POLA | PRPO |
|---|---|---|
| Price | $1.90 | $23.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 19.6K | 8.8K |
| Earning Date | 11-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $8,326,000.00 | ★ $22,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.95 |
| 52 Week Low | $1.53 | $3.90 |
| 52 Week High | $5.75 | $28.50 |
| Indicator | POLA | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 30.17 | 53.04 |
| Support Level | $1.85 | $22.10 |
| Resistance Level | $2.00 | $25.03 |
| Average True Range (ATR) | 0.13 | 1.20 |
| MACD | 0.02 | -0.26 |
| Stochastic Oscillator | 12.73 | 50.76 |
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.